RU2303593C2 - Хиральные производные оксазоларилпропионовой кислоты и их применение в качестве агонистов рецепторов, активированных пролифератором пароксисомы (ppar агонистов) - Google Patents

Хиральные производные оксазоларилпропионовой кислоты и их применение в качестве агонистов рецепторов, активированных пролифератором пароксисомы (ppar агонистов) Download PDF

Info

Publication number
RU2303593C2
RU2303593C2 RU2005114373/04A RU2005114373A RU2303593C2 RU 2303593 C2 RU2303593 C2 RU 2303593C2 RU 2005114373/04 A RU2005114373/04 A RU 2005114373/04A RU 2005114373 A RU2005114373 A RU 2005114373A RU 2303593 C2 RU2303593 C2 RU 2303593C2
Authority
RU
Russia
Prior art keywords
ethoxy
ylmethoxy
methyl
propionic acid
methyloxazol
Prior art date
Application number
RU2005114373/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2005114373A (ru
Inventor
Альфред БИНДЖЕЛИ (CH)
Альфред БИНДЖЕЛИ
Маркус БЁРИНГЕР (CH)
Маркус Бёрингер
Уве ГРЕТЕР (DE)
Уве ГРЕТЕР
Ханс ХИЛЬПЕРТ (CH)
Ханс ХИЛЬПЕРТ
Жорж ИРТ (FR)
Жорж ИРТ
Ханс-Петер МЭРКИ (CH)
Ханс-Петер МЭРКИ
Маркус МЕЙЕР (DE)
Маркус МЕЙЕР
Петер МОР (CH)
Петер Мор
Фабьенн РИКЛЕН (FR)
Фабьенн РИКЛЕН
Original Assignee
Ф.Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф.Хоффманн-Ля Рош Аг filed Critical Ф.Хоффманн-Ля Рош Аг
Publication of RU2005114373A publication Critical patent/RU2005114373A/ru
Application granted granted Critical
Publication of RU2303593C2 publication Critical patent/RU2303593C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
RU2005114373/04A 2002-10-07 2003-10-06 Хиральные производные оксазоларилпропионовой кислоты и их применение в качестве агонистов рецепторов, активированных пролифератором пароксисомы (ppar агонистов) RU2303593C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02022286 2002-10-07
EP02022286.5 2002-10-07

Publications (2)

Publication Number Publication Date
RU2005114373A RU2005114373A (ru) 2006-05-10
RU2303593C2 true RU2303593C2 (ru) 2007-07-27

Family

ID=32049977

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005114373/04A RU2303593C2 (ru) 2002-10-07 2003-10-06 Хиральные производные оксазоларилпропионовой кислоты и их применение в качестве агонистов рецепторов, активированных пролифератором пароксисомы (ppar агонистов)

Country Status (32)

Country Link
US (2) US6969725B2 (es)
EP (1) EP1551814B1 (es)
JP (1) JP4414886B2 (es)
KR (1) KR100623819B1 (es)
CN (1) CN100415727C (es)
AR (1) AR041481A1 (es)
AT (1) ATE402153T1 (es)
AU (1) AU2003273949B2 (es)
BR (1) BR0315114A (es)
CA (1) CA2499721C (es)
CO (1) CO5540385A2 (es)
DE (1) DE60322408D1 (es)
DK (1) DK1551814T3 (es)
ES (1) ES2311110T3 (es)
GT (1) GT200300218A (es)
HK (1) HK1083339A1 (es)
HR (1) HRP20050308A2 (es)
IL (1) IL167250A (es)
MX (1) MXPA05003392A (es)
MY (1) MY143576A (es)
NO (1) NO330171B1 (es)
NZ (1) NZ538465A (es)
PA (1) PA8584501A1 (es)
PE (1) PE20040591A1 (es)
PL (1) PL208743B1 (es)
PT (1) PT1551814E (es)
RU (1) RU2303593C2 (es)
SI (1) SI1551814T1 (es)
TW (1) TWI343915B (es)
UY (1) UY28006A1 (es)
WO (1) WO2004031162A1 (es)
ZA (1) ZA200502664B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009035368A1 (fr) 2007-09-14 2009-03-19 Zakrytoe Aktsionernoe Obschestvo 'masterclone' Composition pharmaceutique possédant un effet antidiabétique

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105551B2 (en) * 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
TWI343915B (en) * 2002-10-07 2011-06-21 Hoffmann La Roche Chirale ppar agonists
OA12960A (en) * 2002-11-15 2006-10-13 Cadila Healthcare Ltd Substituted aralkyl derivatives.
US7262303B2 (en) * 2003-09-29 2007-08-28 Hoffman-La Roche Inc. Process for the production of chiral propionic acid derivatives
KR20080082541A (ko) * 2007-03-07 2008-09-11 동아제약주식회사 퍼옥시좀 증식자-활성화 감마 수용체를 조절하는 신규한페닐프로판산 유도체의 제조방법 및 약학적 용도
JP2012506386A (ja) * 2008-10-21 2012-03-15 メタボレックス， インコーポレイテッド アリールｇｐｒ１２０受容体アゴニストおよびその使用
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
CN101805337B (zh) * 2009-02-13 2012-05-23 天津药物研究院 一类含脯氨酸和异恶唑骨架的化合物、其制备方法和用途
US8637096B2 (en) 2009-12-04 2014-01-28 Curtis C. Stojan Compositions and method for enhancing insulin activity
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
CN102285933B (zh) * 2010-06-18 2016-03-09 浙江海正药业股份有限公司 一种对亚型过氧化物酶增殖物激活受体具有激动作用的化合物、其制备方法和应用
EP2758041B1 (de) 2011-09-20 2021-01-13 Basf Se Niedermolekulare modulatoren des kälte-menthol-rezeptors trpm8 und deren verwendung

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
DE69914557T2 (de) * 1998-03-30 2005-01-05 Japan Tobacco Inc. Verfahren zur herstellung einer isooxazolidindion-verbindung
DE69919156T2 (de) * 1998-05-11 2005-11-03 Takeda Pharmaceutical Co. Ltd. Oxyiminoalkansäure derivate mit hypoglykämischer und hypolipidemischer wirkung
GB9817118D0 (en) * 1998-08-07 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
EP1167357A4 (en) * 1999-04-06 2002-06-05 Sankyo Co ALPHA-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
DE10031657A1 (de) 2000-06-29 2002-01-24 Siemens Ag Hochfrequenz-Bauelement
JP2004506721A (ja) * 2000-08-23 2004-03-04 イーライ・リリー・アンド・カンパニー オキサゾリル−アリールプロピオン酸誘導体およびそのｐｐａｒアゴニストとしての使用
MXPA03010435A (es) * 2001-05-15 2004-03-09 Hoffmann La Roche Derivados de oxazol acido carboxilico sustituidos para uso como activadores de proliferacion del peroximosa(ppar-alfa y gama) en el tratamiento de diabetes.
TWI343915B (en) * 2002-10-07 2011-06-21 Hoffmann La Roche Chirale ppar agonists

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009035368A1 (fr) 2007-09-14 2009-03-19 Zakrytoe Aktsionernoe Obschestvo 'masterclone' Composition pharmaceutique possédant un effet antidiabétique

Also Published As

Publication number Publication date
MY143576A (en) 2011-05-31
US6969725B2 (en) 2005-11-29
AU2003273949B2 (en) 2007-04-05
CA2499721A1 (en) 2004-04-15
CO5540385A2 (es) 2005-07-29
US20050267180A1 (en) 2005-12-01
CA2499721C (en) 2011-03-15
ZA200502664B (en) 2006-02-22
MXPA05003392A (es) 2005-06-22
EP1551814B1 (en) 2008-07-23
HRP20050308A2 (en) 2006-07-31
NO330171B1 (no) 2011-02-28
US20040116487A1 (en) 2004-06-17
NO20051011L (no) 2005-05-02
CN1703406A (zh) 2005-11-30
CN100415727C (zh) 2008-09-03
SI1551814T1 (sl) 2008-10-31
JP4414886B2 (ja) 2010-02-10
UY28006A1 (es) 2004-04-30
US7348349B2 (en) 2008-03-25
PE20040591A1 (es) 2004-08-30
EP1551814A1 (en) 2005-07-13
BR0315114A (pt) 2005-08-16
DK1551814T3 (da) 2008-10-27
WO2004031162A1 (en) 2004-04-15
PA8584501A1 (es) 2004-05-21
PT1551814E (pt) 2008-09-22
AU2003273949A1 (en) 2004-04-23
PL376363A1 (en) 2005-12-27
IL167250A (en) 2010-12-30
AR041481A1 (es) 2005-05-18
HK1083339A1 (en) 2006-06-30
TWI343915B (en) 2011-06-21
ES2311110T3 (es) 2009-02-01
NZ538465A (en) 2007-08-31
PL208743B1 (pl) 2011-06-30
GT200300218A (es) 2004-05-24
ATE402153T1 (de) 2008-08-15
TW200409761A (en) 2004-06-16
KR100623819B1 (ko) 2006-09-13
RU2005114373A (ru) 2006-05-10
KR20050055750A (ko) 2005-06-13
JP2006504709A (ja) 2006-02-09
DE60322408D1 (de) 2008-09-04

Similar Documents

Publication Publication Date Title
JP4330883B2 (ja) 糖尿病の処置においてｐｐａｒ−アルファ及び−ガンマアクチベーターとして使用するためのカルボン酸置換オキサゾール誘導体
ES2295692T3 (es) Nuevos derivados de 4-alcoxioxazol sustituido como agonistas de ppar.
US7348349B2 (en) Oxazole derivatives
US20090047687A1 (en) Indane Acetic Acid Derivatives and Their Use as Pharmaceutical Agents, Intermediates, and Method of Preparation
RU2296754C2 (ru) НОВЫЕ СОЕДИНЕНИЯ 2-АРИЛТИАЗОЛА В КАЧЕСТВЕ АГОНИСТОВ PPAR α И PPAR γ
US20180153860A1 (en) Methods of dose administration for treating or preventing cognitive impairment using indane acetic acid derivatives
US20120141483A1 (en) Methods of treating or preventing psoriasis, and/or alzheimer's disease using indane acetic acid derivatives
JPWO2006126714A1 (ja) ペルオキシソーム増殖剤活性化受容体の活性化剤
US20110065129A1 (en) Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
US20140086910A1 (en) Methods of treating or preventing alzheimer's disease using indane acetic acid derivatives

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20151007